We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Assessment of Pain Severity after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma.
OBJECTIVE: To find the incidence of moderate to severe pain after percutaneous radiofrequency ablation (RFA) in patients with hepatocellular carcinoma and to identify the factors affecting unwanted pain scores.
MATERIAL AND METHOD: This prospective study was conducted on patients who underwent percutaneous radiofrequency ablation under intravenous sedation and local anesthesia. The pain scores were obtained from 18 to 24 hours after the procedure. Moderate to severe pain was defined as a value of 4 or more on the Numeric Rating Scale (NRS). Data on patients' factors, tumor characteristics, procedural factors, anesthetic management, postoperative treatment and perioperative complication was collected
RESULTS: A total of 190 patients were enrolled, comprised of 134 men (70.5%) and 56 women (29.5%). The mean age of the patients was 63.3 ± 11.1 years. The incidence of moderate to severe pain on movement (an NRS value equal to or greater than 4) was 11.6% (22 out of 190 patients). A univariate analysis revealed that two factors--patients with multiple tumors (more than two tumors), and an ablation time of greater than 30 minutes--seemed to be related to an NRS equal to or greater than 4. Nevertheless, after entering those two factors into a multiple regression model, neither factor was associated with the moderate to severe pain scores.
CONCLUSION: The incidence of undesired pain scores after percutaneous radiofrequency ablation in our institution was around 10%, and the rate of complication was very low.
MATERIAL AND METHOD: This prospective study was conducted on patients who underwent percutaneous radiofrequency ablation under intravenous sedation and local anesthesia. The pain scores were obtained from 18 to 24 hours after the procedure. Moderate to severe pain was defined as a value of 4 or more on the Numeric Rating Scale (NRS). Data on patients' factors, tumor characteristics, procedural factors, anesthetic management, postoperative treatment and perioperative complication was collected
RESULTS: A total of 190 patients were enrolled, comprised of 134 men (70.5%) and 56 women (29.5%). The mean age of the patients was 63.3 ± 11.1 years. The incidence of moderate to severe pain on movement (an NRS value equal to or greater than 4) was 11.6% (22 out of 190 patients). A univariate analysis revealed that two factors--patients with multiple tumors (more than two tumors), and an ablation time of greater than 30 minutes--seemed to be related to an NRS equal to or greater than 4. Nevertheless, after entering those two factors into a multiple regression model, neither factor was associated with the moderate to severe pain scores.
CONCLUSION: The incidence of undesired pain scores after percutaneous radiofrequency ablation in our institution was around 10%, and the rate of complication was very low.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app